A phase 3 trial of sunitinib alone versus nephrectomy followed by sunitinib in patients with intermediate- and poor-risk metastatic renal cell carcinoma (RCC) suggests surgery may not always be necessary. The CARMENA trial presented at the ASCO 2018 meeting and published in NEJM found overall survival was better in patients treated with the targeted therapy ...
Will the CARMENA trial change your practice?
By Mardi Chapman
7 Jun 2018